Immunologic targeting of the cancer stem cell

Wu, Catherine J.

doi:10.3824/stembook.1.21.1

Cited by 6 publications

(4 citation statements)

References 221 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies to identify the OS cancer stem cells (CSCs) or tumor‐initiating cells (TICs) highlight a number of available techniques used to isolate and enrich TICs: (1) the sphere culture assay (or sarcosphere assay) ; (2) cell sorting for CD133, high‐ALDH activity, SP cells, or CD117 in combination with Stro‐1 ; (3) identification of cells that express the embryonic stem cell gene Oct‐4 ; and (4) resistance to chemotherapeutic drugs using U2OS and MG63 cell lines . The above studies shed light on the tumor initiation of OS, however, not much is known about the OS progression.…”

Section: Introductionmentioning

confidence: 99%

High CD49f expression is associated with osteosarcoma tumor progression: a study using patient‐derived primary cell cultures

et al. 2014

View full text Add to dashboard Cite

Overall prognosis for osteosarcoma (OS) is poor despite aggressive treatment options. Limited access to primary tumors, technical challenges in processing OS tissues, and the lack of well-characterized primary cell cultures has hindered our ability to fully understand the properties of OS tumor initiation and progression. In this study, we have isolated and characterized cell cultures derived from four central high-grade human OS samples. Furthermore, we used the cell cultures to study the role of CD49f in OS progression. Recent studies have implicated CD49f in stemness and multipotency of both cancer stem cells and mesenchymal stem cells. Therefore, we investigated the role of CD49f in osteosarcomagenesis. First, single cell suspensions of tumor biopsies were subcultured and characterized for cell surface marker expression. Next, we characterized the growth and differentiation properties, sensitivity to chemotherapy drugs, and anchorage-independent growth. Xenograft assays showed that cell populations expressing CD49fhi/CD90lo cell phenotype produced an aggressive tumor. Multiple lines of evidence demonstrated that inhibiting CD49f decreased the tumor-forming ability. Furthermore, the CD49fhi/CD90lo cell population is generating more aggressive OS tumor growth and indicating this cell surface marker could be a potential candidate for the isolation of an aggressive cell type in OSs.

show abstract

Section: Introductionmentioning

confidence: 99%

High CD49f expression is associated with osteosarcoma tumor progression: a study using patient‐derived primary cell cultures

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Methods manipulating the graft immune activity towards GVL with minimizing GVHD represent a new exciting direction which could promote the next breakthrough in allogeneic HSCT. Graft-versus-leukemia is mainly attributed to the immune response of donor T lymphocytes against residual or relapsed leukemic cells, as well as to the immune response of natural killer (NK) cells and B lymphocytes 49. Among the leading strategies that have already reached the clinical phase of investigation are graft manipulations in the setting of haploidentical HSCT, vaccinations against tumor-associated antigens (TAA), monoclonal antibodies, and targeted adoptive cellular immunotherapy.…”

Section: Future Perspectivesmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives

Henig¹,

Zuckerman²

2014

Rambam Maimonides Med J

169

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation is a highly specialized and unique medical procedure. Autologous transplantation allows the administration of high-dose chemotherapy without prolonged bone marrow aplasia. In allogeneic transplantation, donor-derived stem cells provide alloimmunity that enables a graft-versus-tumor effect to eradicate residual disease and prevent relapse. The first allogeneic transplantation was performed by E. Donnall Thomas in 1957. Since then the field has evolved and expanded worldwide. New indications beside acute leukemia and aplastic anemia have been constantly explored and now include congenital disorders of the hematopoietic system, metabolic disorders, and autoimmune disease. The use of matched unrelated donors, umbilical cord blood units, and partially matched related donors has dramatically extended the availability of allogeneic transplantation. Transplant-related mortality has decreased due to improved supportive care, including better strategies to prevent severe infections and with the incorporation of reduced-intensity conditioning protocols that lowered the toxicity and allowed for transplantation in older patients. However, disease relapse and graft-versus-host disease remain the two major causes of mortality with unsatisfactory progress. Intense research aiming to improve adoptive immunotherapy and increase graft-versus-leukemia response while decreasing graft-versus-host response might bring the next breakthrough in allogeneic transplantation. Strategies of graft manipulation, tumor-associated antigen vaccinations, monoclonal antibodies, and adoptive cellular immunotherapy have already proved clinically efficient. In the following years, allogeneic transplantation is likely to become more complex, more individualized, and more efficient.

show abstract

“…CD133 is expressed in hematopoietic stem cells, neural stem cells, and some other cell types ( 26 – 30 ). CD133 + cells are thought to be glioma initiating cells in the brain, with its tumorigenicity much higher than than CD133 − cells ( 31 , 32 ). Interestingly, CD133+ cells are extensively present in the clinical head and neck squamous cell carcinoma specimens and possess stem cell-like properties in vitro ( 33 ) and promote the initiation of head and neck cancer ( 34 ).…”

Section: Introductionmentioning

confidence: 99%

Id1 and NF-κB promote the generation of CD133+ and BMI-1+ keratinocytes and the growth of xenograft tumors in mice

Lai

Cai

Biel

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

Id1 and NF-κB are highly expressed in oral squamous cell carcinoma (OSCC). Whether they have a synergistic role in the carcinogenesis of OSCC is unclear. The current study was designed to demonstrate the synergy of both Id1 and NF-κB in the underlying disease mechanisms of OSCC using in vitro and in vivo animal models. Id1 and NF-κB strengthened the expression of both CD133 and BMI-1 in OSCC cell cultures. CD133+ and BMI-1+ keratinocytes from OSCC tissues and cell cultures initiated the growth of xenograft tumors in SCID/Beige mice. Id1 and NF-κB regulate the expression of CD133 and BMI-1 in an additive or synergistic manner in OSCC, which is associated with the generation of naïve and self-renewable keratinocytes and initiate the growth of xenograft tumors in vivo.

show abstract

Immunologic targeting of the cancer stem cell

Cited by 6 publications

References 221 publications

High CD49f expression is associated with osteosarcoma tumor progression: a study using patient‐derived primary cell cultures

High CD49f expression is associated with osteosarcoma tumor progression: a study using patient‐derived primary cell cultures

Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives

Id1 and NF-κB promote the generation of CD133+ and BMI-1+ keratinocytes and the growth of xenograft tumors in mice

Contact Info

Product

Resources

About